Related Experiment Video
Updated: Feb 11, 2026
Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
Published on: June 18, 2013
Drug-induced amplification of nanoparticle targeting to tumors
Kevin Y Lin1, Ester J Kwon2, Justin H Lo3,4
1Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139.
Abstract:
Nanomedicines have the potential to significantly impact cancer therapy by improving drug efficacy and decreasing off-target effects, yet our ability to efficiently home nanoparticles to disease sites remains limited. One frequently overlooked constraint of current active targeting schemes is the relative dearth of targetable antigens within tumors, which restricts the amount of cargo that can be delivered in a tumor-specific manner. To address this limitation, we exploit tumor-specific responses to drugs to construct a cooperative targeting system where a small molecule therapeutic modulates the disease microenvironment to amplify nanoparticle recruitment in vivo. We first administer a vascular disrupting agent, ombrabulin, which selectively affects tumors and leads to locally elevated presentation of the stress-related protein, p32. This increase in p32 levels provides more binding sites for circulating p32-targeted nanoparticles, enhancing their delivery of diagnostic or therapeutic cargos to tumors. We show that this cooperative targeting system recruits over five times higher doses of nanoparticles to tumors and decreases tumor burden when compared with non-cooperative controls. These results suggest that using nanomedicine in conjunction with drugs that enhance the presentation of target antigens in the tumor environment may be an effective strategy for improving the diagnosis and treatment of cancer.
Insights
This study introduces a cooperative targeting system for nanomedicine in cancer therapy. By using a drug to increase tumor-specific binding sites, it significantly enhances nanoparticle delivery and reduces tumor burden.
Area of Science:
- Oncology
- Nanomedicine
- Drug Delivery
Background:
- Nanomedicines offer improved cancer therapy but face challenges in targeted delivery due to limited antigens in tumors.
- Current active targeting strategies are constrained by the scarcity of targetable antigens within tumor sites.
Purpose of the Study:
- To develop a cooperative targeting system that enhances nanoparticle delivery to tumors by modulating the tumor microenvironment.
- To overcome the limitation of scarce tumor-specific antigens for improved nanomedicine efficacy.
Main Methods:
- Administered ombrabulin, a vascular disrupting agent, to selectively target tumors and increase p32 protein presentation.
- Utilized p32-targeted nanoparticles to bind to the upregulated protein, enhancing tumor recruitment.
- Compared the cooperative targeting system with non-cooperative controls in a tumor model.
Main Results:
- The cooperative targeting system increased nanoparticle delivery to tumors by over fivefold compared to controls.
- Demonstrated a significant decrease in tumor burden using the enhanced nanoparticle delivery strategy.
- Ombrabulin administration led to locally elevated presentation of the stress-related protein p32 in tumors.
Conclusions:
- Exploiting tumor-specific drug responses to enhance antigen presentation is a viable strategy for cooperative nanomedicine targeting.
- This approach significantly improves the delivery of diagnostic and therapeutic nanoparticles to tumors.
- Cooperative targeting holds promise for advancing cancer diagnosis and treatment through enhanced nanomedicine efficacy.
Related Concept Videos
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
02:35RACE - Rapid Amplification of cDNA Ends
01:25Pharmacokinetics: Drug–Drug Interactions
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...